Clinical Trial Update: Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given With Priorix™ in Toddlers (13-14 m) Primed With 3 Doses of Hib and MenC-CRM197 [Phase 3]

View source ↗

Summary

Phase 3 safety, reactogenicity and immunogenicity study evaluating a booster dose of Hib-MenC given with Priorix in toddlers previously primed with Hib and MenC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Disease
• Meningococcal Disease

Drugs mentioned

• Hib-MenC-CRM197 vaccine
• Priorix (Measles-Mumps-Rubella Vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Haemophilus Influenzae Type b, Neisseria Meningitidis | Phase 3 | Status: COMPLETED